NASDAQ:LABT Lakewood-Amedex Biotherapeutics Q2 2026 Earnings Results & Report $0.28 0.00 (0.00%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$0.28 0.00 (-0.85%) As of 11/13/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Lakewood-Amedex Biotherapeutics reported Q2 2026 earnings on August 14, 2026. The company reported EPS of -$2.75. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 14, 2026TimeBefore Market OpensConference Call7:00 AM ET Lakewood-Amedex Biotherapeutics EPS ResultsActual EPS-$2.75Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ALakewood-Amedex Biotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Lakewood-Amedex Biotherapeutics Q2 2026 Earnings FAQ Did Lakewood-Amedex Biotherapeutics beat earnings estimates for Q2 2026? Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) reported earnings of -$2.75 per share for Q2 2026. The report was announced on Friday, August 14, 2026. Lakewood-Amedex Biotherapeutics Earnings HeadlinesLakewood-Amedex Biotherapeutics (NASDAQ:LABT) Cut to Strong Sell at Wall Street ZenNovember 10, 2026 | americanbankingnews.comLakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock RedemptionNovember 5, 2026 | insidermonkey.comURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it. | Paradigm Press (Ad)Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock RedemptionNovember 5, 2026 | prnewswire.comLakewood-Amedex Biotherapeutics consensus price target decreased by 37.50% to $7.65November 2, 2026 | msn.comHC Wainwright & Co. initiates coverage of Lakewood-Amedex Biotherapeutics with buy ratingOctober 28, 2026 | msn.comSee More Lakewood-Amedex Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lakewood-Amedex Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lakewood-Amedex Biotherapeutics and other key companies, straight to your email. Email Address About Lakewood-Amedex BiotherapeuticsLakewood-Amedex Biotherapeutics (NASDAQ:LABT), Inc. is a biotechnology company focused on the research and development of anti-infective therapies. Its work centers on developing treatments designed to address infections caused by bacteria and other pathogens. The company’s activities are primarily directed toward advancing a pipeline of investigational therapeutic candidates rather than selling a broad portfolio of marketed products. Its development programs have focused on potential applications in human health, including treatments for localized and systemic infections. Publicly available information about Lakewood-Amedex Biotherapeutics’ current product pipeline, commercial operations, geographic reach, and leadership is limited. The company should therefore be regarded primarily as a development-stage biotechnology enterprise.View Lakewood-Amedex Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?Applied Materials Beats and Raises, But Investors Stay Unconvinced3 Power and Grid Stocks That Could Keep Growing Even if AI Spending SlowsYETI Beat on Earnings, But Its Sales Tell a Different Story Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.